Edgen Stock·Oct 13 2025, 13:25Back
Back
AstraZeneca Prepares to Unveil Extensive Oncology Trial Data at ESMO Congress
Edgen Stock·Oct 13 2025, 13:25
[1] AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO[2] Daiichi Sankyo (4568 JP): Mixed Q3FY25 Result; FY25 Net Profit Guidance Raised; New CEO Appointed - Tina Banerjee - Smartkarma[3] AstraZeneca (AZN) Showcases New Data at ESMO Congress 2025 - GuruFocus